Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ondansetron + dexmedetomidine
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of ondansetron, a serotonin 5-HT3 receptor antagonist, and dexmedetomidine, a highly selective α-2 adrenergic receptor agonist. This combination is used primarily for the prevention of postoperative nausea and vomiting (PONV). Ondansetron works by blocking serotonin receptors in the vomiting center, while dexmedetomidine provides sedative, anxiolytic, and analgesic effects. Studies have shown this combination to be effective in reducing PONV in various surgical settings, though there are concerns about potential QT interval prolongation when used together.
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)ADRA2A (α2A)
Beyond the preview
Go deeper on ondansetron + dexmedetomidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ondansetron + dexmedetomidine.